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Plasminogen activators, enzymes which convert the proenzyme plasminogen
to its proteolytically active form (plasmin), have been recognized in a variety of
cells, tissues, and body fluids (1). The best characterized of these plasminogen
activators is urokinase, a serine protease of mol wt 54,000 which is found in the
urine of normal adults (2). Kucinski et al. (3) prepared a guinea pig antiserum
against human urokinase. This antiserum inhibited the plasminogen-activating
capacity of human and primate urokinases and the plasminogen activator
secreted by cultured adult kidney cells. Since the antibody had no inhibitory
effects upon plasminogen activators produced by other human tissues or body
fluids Kucinski et al. (3) concluded that urokinase is produced by the kidney and
that it is immunologically distinct from plasminogen activators produced
elsewhere in the body.
Unkeless et al . (4), Ossowski et al. (5), and Rifkin et al. (6) have reported that a variety
of transformed cells and primary explants of human tumors actively secrete plasminogen
activators in vitro. Pollack et al. (7) have found a strong correlation between plasminogen
activator secretion and the capacity of cells to grow in semisolid medium, and Christman
et al. (8) have shown that the capacity of mouse melanoma cells to secrete plasminogen
activators is closely correlated with tumorigenic potential of these cells in vivo. Despite
these correlations, the role of plasminogen activators in tumorigenicity remains obscure.
Recently, Christman and Acs (9) purified a plasminogen activator secreted by a line of
SV40-transformed hamster embryo cells. Their most highly purifed preparation had a
specific activity 14,000-fold above that of the starting material, exhibited a single
Coomassie blue stained band on SDS-polyacrylamide gel electrophoresis, and had a mol
wt of 50,000. This enzyme had an isoelectric point of pH of 9.5 and was shown to be a
serine protease composed of at least two subunits joined by disulfide linkages. The
catalytic subunit, identified by labeling with ['H]diisopropylphosphofluoridate had a mol
wt of 25,000.
' Supported by grant NP636K from the American Cancer Society, grants CA16890 and AI08697
from theU. S. Public Health Service, and by The Muscular Dystrophy Association.
f Established Investigator of the American Heart Association.
THE JOURNAL OF EXPERIMENTAL MEDICINE " VOLUME 142, 1975
￿
419420
￿
IMMUNOLOGICAL ANALYSIS OF PLASMINOGEN ACTIVATORS
The characterization of this enzyme and the availability of several alternative methods
for its purification (10) have enabled us to prepare antibodies against it. These antibodies
have been used to compare the immunological properties of this particular enzyme with
those of plasminogen activators from normal tissues andwith plasminogen activators from
other transformed cells.
In this report, we describe the preparation and specificity of antibodies against
the plasminogen activator produced by a line of SV40-transformed hamster cells.
The antibody inhibits the enzymatic activity of the cell-bound and secreted
forms of this plasminogen activator, prevents the release of SV40-transformed
hamster cells from the growth surface (4), and forms a single precipitin line on
immunoduffusion using purified SV40 hamster plasminogen activator as
antigen. The antibody is species specific; it does not inhibit plasminogen
activators derived from normal or transformed human cells or from transformed
murine cells. Most importantly, the antibody appears to discriminate between
plasminogen activators from different tissues of the same organism since it
inhibits the plasminogen activator(s) produced by an established line of hamster
lung cells and by a primary explant of newborn hamster lung but it has no
inhibitory effect upon plasminogen activator(s) secreted by an established line of
hamster kidney cells or a primary explant of newborn hamster kidney.
Materials and Methods
Cell Cultures. Hamster cell lines HaK and DON were obtained from the American Type
Culture Collection, Rockville, Md., and maintained in Dulbecco's Modified Eagle's Medium supple-
mented with 10 and 20%fetal bovine serum, respectively. Primary explants of hamster, lung, kidney,
and skin were obtained by trypsinization (0.25%) of the appropriate organs of 2- to 3-day old Syrian
hamsters (Lakeview Hamster Colony, Newfield, N. J.). The cells were grown in Dulbecco's medium,
containing 10% fetal bovine serum. SV40 virus-transformed hamster embryo cells (5), the kind gift of
Doctors E. Reich and L. Ossowski, both from The Rockefeller University, were maintained in the
same medium. Mouse melanoma clones B,59 and B,e were the kind gift of Dr. S. Silagi, Cornell Uni-
versity Medical College, New York. Their derivation and maintenance is described in reference 11.
The mouse mammary tumor line was the gift of Dr. S. Spiegelman. Powdered media and dog serum
were from Grand Island Biological Corp., Grand Island, N. Y., and fetal bovine serum from Flow
Laboratories, Inc., Rockville, Md.
Enzymes.
￿
The purification of plasminogen activator from SV40-transformed hamster cells has
been described in detail (9, 10) . Plasminogen activator released from HaKcells waspurified using the
sarr)e methods. The plasminogen activator preparations utilized for these studies were as follows: (a)
Harvest fluid (HF),' the serum-free medium containing plasminogen activator released by cells;
Tables III and IV. (b) Protein from a 50% (NH,),SO, precipitate of HF dissolved in 0.05 M glycine-
HCI, pH 4.0, and extensively dialyzed against this buffer [stage 3, (9) approximately eight-fold
purification]; Tables I and IV. (c) 0.5 M (NH,),SO, eluate from SP-C25 Sephadex, dialyzed and
concentrated against 0.05 M glycine-HCI, pH 4.0 [stage 5, (9) approximately 400-fold purification];
Table IV and Figs. 2, 3, and 4, and as immunogen to prepare antiplasminogen activator antibody
(APA-IgG) . Purification of plasminogen activator by high-voltage liquid-phase isoelectric focusing
has also been described (10). Such preparations (Figs. 2and 4) display asingle protein band of mol wt
50,000 on SDS-polyacrylamide gel electrophoresis.
Cell-bound enzyme was a plasma membrane-enriched fraction prepared from HaK, DON, and
SV40-transformed hamster cells using the method of Atkinson and Summers (12). Cells were
'Abbreviations used in this paper: APA, antiplasminogen activator; CFA, complete Freund's
adjuvant ; FDP, fibrin degradation products; HBSS, Hanksbalanced salt solution without phenol red;
HF, harvest fluid; PBS, phosphate-buffered saline; SAR-IgG, sheep antibody to rabbit IgG.J . K. CHRISTMAN, S. C. SILVERSTEIN, AND G. ACS
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harvested by scraping and lysed according to the methodsused in references 10 and 12. Afterremoval
of nuclei, large membrane fragments and "ghosts" were pelleted at 6-10,000 g and suspended in
buffer containing 0.01 M Tris-HCl, pH 8.0, 0.01 M NaN,, 0.01 MNaCl, and 0.003 M Mg acetate at a
concentration of approximately 10' cells/ml. These preparations were used for the experiments
shown in Tables I andIV andas immunogen to prepare anti-SV40 hamster cell membrane antibody.
Plasminogen Activator Assays.
￿
All assays for plasminogen activator are based on the capacity of
this enzyme to convert plasminogen to plasmin. Plasmin activity was determined by its ability to
release '261-labeled fibrin degradation products (FDP) from 1251-labeled fibrin-coated petri dishes. The
standard 35 mm dish used for all determinations was coated with approximately 0.1 mg
1151_labeled
fibrinogen containing 100,000 cpm. Two forms of the assay were used. (a) Cells were plated directly
on radioactive fibrin layers andserved as the source of plasminogen activator. Dog serum (10%) was
plasminogen source. (b) Purified plasminogen activator or cell-free HF was incubated in afinal vol of
1 ml 0.1 M Tris-HCl, pH 8.1, containing 4 jug of dog plasminogen [purified by lysine affinity
chromatography (13)]. Release of 1261-labeled FDP was determined directly by measuring the
radioactivity of the incubation mixture in a Nuclear Chicago scintillation counter (Nuclear-Chicago
Corp., Des Plaines, Ill.) with Hydromix (Yorktown Research, N. Y.) as fluor.
Cytotoxicity Assays.-Adsorbed guinea pig complement (C) : SV40-transformed hamster cells in
monolayer cultures were washed three times with 5 ml of phosphate-buffered saline (PBS) (pH 7.4)
[solution A of Dulbecco and Vogt (14)], and removed from the monolayer by incubation at room
temperature for approximately 10 min in 0.25% trypsin (GIBCO) in the same buffer. 5 ml of
Dulbecco's medium containing 10% fetal bovine serum were added to inhibit further proteolysis, the
cells were pelleted at 250g for 10 min at 4°C, and resuspended in Hanks' balanced salt solution
without phenol red (HBSS), pH 7.4, (GIBCO) at a concentration of 2 x 10' cells/ml (>97% viable by
trypan blue exclusion). Whole C (lot no. TO 933) from Cordis Laboratories, Miami, Fla., was
resuspended in 5 ml HBSS. 0.5 ml of this C solution was incubated for 30 min at 4°C with 1 x 10'
hamster cells in 0.5 ml ofHBSS. The cells were removed by centrifugation (250 g, 10 minat 4°C) and
the clear supernate was diluted with an equal volume of HBSS. This final solution is referred to as
adsorbed C.
Antisera.
￿
Sheep antibody to rabbit IgG (SAR-IgG) was the IgG fraction of sheep serum obtained
after DEAE-cellulose column chromatography as described previously (15). 5 x 10' SV40 hamster
cells in monolayer culture were trypsinized, pelleted by centrifugation, and incubated in 1 ml of SAR
IgG (40 mg/ml in PBS) for 2 h at 4°C. The cells were pelleted (250 g, 10 min at 4°C) and the
supernatant solution is the adsorbed SAR-IgG used in the experiment described in Table V.
Rabbit anti-SV40 hamster cell plasminogen activator IgG (APA-IgG) wasprepared as follows: 2 ml
of plasminogen activator (stage 5 purification) containing in each milliliter an amount of
plasminogen activator activity equivalent to that found in approximately 26 jug of the isoelectrically
focused purified enzyme was mixed with 1 ml of complete Freund's adjuvant (CFA) (Difco
Laboratories, Detroit, Mich.). Abrown rabbit wasinjected intramuscularly and subcutaneously with
this material. 18 days later 0.5 ml of the same plasminogen activator solution (without Freund's
adjuvant) wasinjected into each hind foot pad, and the rabbit was bled 2 wk later. The IgG fraction
from 30 ml of serum wasobtained by DEAE-cellulose column chromatography (15), brought to a final
concentration of 30 mg/mlin PBS andused for the studies described in Tables 1, 11, III, IV, and V, and
Fig. 2. 4 mo after the initial bleeding the rabbit wasgiven a second injection of 3.5 lag ofisoelectrically
purified plasminogen activator in CFA, bled 7days later, andthe IgGfraction purified as above. This
preparation (45 mg/ml) was used for the experiments described in Figs. 2b, 3, and4.
Rabbit anti-SV40 hamster cell membrane IgG (30 mg/mlin PBS) wasprepared as follows: Awhite
New Zealand rabbit wasinjected subcutaneously andintramuscularly with a cell membrane-enriched
fraction (prepared as described above from approximately 2 x 10' SV40 hamster cells) in CFA, and
18 days later in the foot pads with the same membrane fraction (from 1 x 101 cells) in PBS. 2wk later
the rabbit wasbled and an IgG fraction obtained by DEAE-cellulose chromatography (15).
Rabbit anti-SV40 hamster cell IgG (13 mg/ml in PBS) was similarly prepared by injecting a white
New Zealand rabbit with a total of approximately 5 x 106 viable SV40 hamster cells both
intravenously and intramuscularly following the immunization schedule described above. A control
IgG fraction (9 mg/ml) was similarly prepared from an unimmunized rabbit which had not been
actively challenged with any hamster protein (9 mg/ml).
Immunodiffusion.
￿
The studies described in Fig. 2 were performed using immunodiffusion plates422
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from Hyland Div., Travenol Laboratories, Inc., Costa Mesa, Calif. Immunodiffusion in Noble agar
(Difco Laboratories) containing bovine fibrinogen (Pentex Biochemical, Kankakee, Ill.) (Fig. 4) was
performed exactly as described by Clausen (16), except that 4.2 gg of purified dog plasminogen were
added for each ml of fibrinogen-containing agar.
Results
Inhibition of Cell-Bound and Secreted SV40 Hamster Plasminogen Activator
by APA-IgG. APA-IgG effectively inhibited the action of both the released and
cell-associated forms of plasminogen activator from SV40-transformed hamster
cells. IgG from the serum of normal rabbits or rabbits immunized with
SV40-transformed hamster cells had no inhibitory effect on either enzyme
preparation (Table 1) . IgG from rabbits immunized with a plasma
membrane-enriched fraction of SV40-transformed hamster cells (containing
cell-associated plasminogen activator) hadno effect on activation of plasminogen
by released enzyme but did inhibit the cell-associated enzyme at high antibody
concentrations (Table I) . This inhibition of the cell-bound but not the released
form of plasminogen activator by anti-SV40 hamster cell membrane IgG is
unexplained. The anti-SV40 hamster cell membrane IgG does not cross react
with purified plasminogen activator as measured by immunodiffusion in agar
gels. Since the intracellular form of the enzyme is tightly bound to cellular
membranes (10), it is possible that the interaction of antibody molecules with
nearby membrane antigens sterically limits access of plasminogento the enzyme.
It is also possible that the intracellular form of plasminogen activator contains
additional antigenic determinants which are not present on the secreted enzyme.
This is indeed the case for insulin (17) . Resolution of this question awaits a
reliable method for solubilizing the intracellular form of the enzyme.
The release of FDP by SV40-transformed hamster cells plated on 1251-labeled
fibrin-coated Petri dishes in the presence of suitable serum was also inhibited by
APA-IgG (Table 1I). The data in Table 11 are from a typicalexperiment where the
number of cells plated and the incubation time are such that the release of FDP
by the control culture is between 50-80% of maximal release. If the incubation
time is extended, all of the cultures, even those which are totally inhibited at 24 h,
eventually release the maximal amount of 1251-labeled fibrin.
When SV40-transformed hamster cells were grown in monolayer culture
supplemented with dog serum they activated sufficient plasmin to cause release
of the cells from the growth surface (Fig. 1 a and reference 5) . Addition of
APA-IgG to the culture medium did not slow cellular growth or inhibit the "piled
up" appearance of these cells, but did prevent the release of the cells from the
surface of the Petri dish (Fig. 1 b). The duration of this inhibition was dependent
upon the quantity of added APA-IgG. Once the inhibitory capacity of the
antibody was saturated, plasmin was generated and the cells were released from
the Petri dish. Two conclusions may be drawn from these experiments: (a)
APA-IgG does not inhibit release of plasminogen activator from
SV40-transformed hamster cells since cells treated with this antibody are able to
secrete sufficient plasminogen activator to exhaust the neutralizing capacity of
the antibody . (b) The cell-bound and secreted forms of plasminogen activatorJ . K. CHRISTMAN, S. C. SILVERSTEIN, AND G. ACS
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TABLE I
Effect of Several IgG Preparations on the Activation ofPlasminogen by Enzyme(s) from
SV40 Virus-Transformed Hamster Fibroblasts
Source ofenzyme
Released
The indicated IgG andenzyme preparations were incubated on "5I-labeled fibrin-coated assay plates
at 23°C in 0.5 ml of 0.1 MTris, pH 8.1. After 15 min, 4 ug of dogplasminogen in 0.5 ml of the same
buffer were added and incubation continued at 37°C for 2 h. The IgG concentration given is that
present during the final incubation. Released enzyme wasat stage 3 of purification (9) and hadbeen
concentrated and dialyzed against 0.05 M glycine-HCI, pH 4.0, in a Prodicon vacuum dialyzer (Bio-
Molecular Dynamics, Beaverton, Oreg.). (Degree of purification had no effect on the inhibition of
plasmin formation by APA-IgG when the enzyme preparation was properly desalted.) The cell mem-
brane-enriched fraction was prepared as described in theMaterials and Methods. All data have been
corrected for "°I released into medium containing plasminogen alone. Enzyme or IgG without added
plasminogen released fewer counts than plasminogen.
activator IgG 3
6
14.5
29
145
7,330
4,828
1,340
0
0
42
27
8
0
0
Antihamster cell 0 14,300 100
membrane IgG 29 18,900 132
58 23,450 163
145 14,000 90
290-2,900 14,000-15,730 100-110
Antihamster cell <145 100-150
IgG
Control rabbit IgG <450 100-110
SV-40 hamster cell Antiplasminogen 0 19,800 100
membrane enriched activator IgG 3 4,300 22
fraction 6 2,700 14
14.5 270 1
29 0 0
0 15,000 100
Antihamster cell 29 12,800 85
membrane IgG 145 6,770 45
290 2,864 19
580-2,900 0 0
Antihamster cell :51,300 90-110
IgG
Control rabbit IgG <_360 100
I'll-labeled
Control IgGpreparation
concentration FDPcpmreleased
2 h, 37°C
activity
ugprotein/ml %
Antiplasminogen 0 17,700 100424
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TABLE II
Effect of AntiplasminogenActivatorIgG on the Release of Fibrin DegradationProducts by
SV40-Transformed Cells
Cells (5 x 105) were plated on sterile '25I-labeled fibrin-coated dishes in modified Eagle's medium.
After 4-5 h at 37°C, the indicated amount of IgG was added, incubation wascontinued for 30 min,
and then dogserum was added to a final concentration of 10%. The final vol was3 ml.
* Corrected for 125I released into medium containing dog serum without added cells. Cells without
added serum released fewer counts than dog serum alone .
contain similar immunological determinants since both are inhibited by
APA-IgG.
Immunological Characterization of Plasminogen Actiuator. APA-IgG was
prepared using SV40 hamster cell plasminogen activator (purified to stage 5, see
Materials and Methods) as the immunogen. As a consequence, the APA-IgG
contained antibodies to several antigens which are present in this partially
purified material. Analysis of two such partially purified plasminogen activator
preparations by double diffusion in agar gels against APA-IgG revealed several
distinct precipitin lines (Fig. 2 a, well nos. 2 and 4). Further purification of the
plasminogen activator by high-voltage liquid-phase isoelectric focusing resulted
in a highly purified (one band on SDS gel electrophoresis) and enzymatically
active preparation which gave a single precipitin line on immunodiffusion (Fig. 2
b) . This precipitin line is identical to one of the lines found in the partially
purified plasminogen activator (Fig. 2 a, well no. 3). Immunoelectrophoretic
analysis of partially purified plasminogen activator showed two precipitin lines,
only one of which corresponds to the electrophoretic mobility of plasminogen
activator (Fig . 3) . Confirmation that the lighter precipitin band is formed by
precipitation of the plasminogen activator by APA-IgGwas achieved by diffusion
in gels containing fibrinogen and plasminogen. As shown in Fig. 4, there is good
correspondence between the zone of inhibition of fibrinolysis and the single
precipitin line formed between isoelectrically focused purified plasminogen
activator and APA-IgG. Partially purified plasminogen activator exhibits two
precipitin lines in this assay; a dense precipitin line whose position does not
correspond to the zone of inhibition of fibrinolysis, and a light precipitin line
whose position corresponds to the zone of inhibition of fibrinolysis but is obscured
by it. The inhibition of fibrinolysis is immunologically specific . Control rabbit
IgG preparations did not inhibit fibrinolysis mediated by SV40 hamster
cell-secreted plasminogen activator and APA-IgG did not inhibit fibrinolysis
mediated by hamster kidney cell-secreted plasminogen activator.
Species Specificity of APA-IgG.
￿
Table III summarizes the results of anumber
of experiments demonstrating the lack of effect of APA-IgG on the ability of
IgG concentration Released 1251-labeled FDP
cpm 24 h, 37°C*
Control activity
Ag protein/105 cells
0 39,700 100
116 31,800 80
230 11,910 30
580 0 0FIG . 1 . Effect of APA-IgG on the ability of SV40-transformed hamster cells to remain
attached to the growth surface in the presence of a plasminogen source . Cells were plated at a
density of 5 x 10 5 on 35 mm Petri dishes coated with fibrin . (Procedure exactly as described in
Table II .) (a) No APA-IgG added . (b) 300uglml of APA-IgG added . Both cultures contain 10%
dog serum and have been incubated at 37°C for approx 18 h . x 500 .
425426
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FIG. 2 .
￿
Ouchterlony immunodiffusion analysis of SV40 hamster cell plasminogen activator
preparations . (a) Center well, 10 j1 APA-IgG. Well 1, 10 Al 0.05M glycine-HCI buffer, pH 4.0 ;
wells 2 and 4, 10 jil stage5plasminogen activator in thesame glycine-HCI buffer ; andwell 3, 10
pl isoelectrically focused plasminogen activator . (b) Center well, 10 Al isoelectrically focused
plasminogen activator . Well 1, 10 g1 anti-SV40 cell membrane IgG. Well 2, 10 Al APA-IgG (first
preparation, 30 mg/ml) and wells3 and 4, APA-IgG (second preparation, 45 mg/ml) . Well 5, 10
,1 controlIgG. Both APA-IgG preparations give a precipitin line of identity against the highly
purified plasminogen activator . Note the absence of spurring which is seen in figure 2a using
the partially purified enzyme as antigen .
FIG. 3.
￿
Immunoelectrophoretic analysis of stage 5 plasminogen activator . Glass slides (25 x75
(mm) were coated with 3ml of 2% Nobleagar in 0.05 ionic strength barbital buffer (pH 8) . 20 Al
of a partially purified plasminogen activator preparation (stage 5, reference 9) was placed in
the center well andelectrophoresed at room temperature at 5V/cm for 2 h. The agar stripwas
then divided longitudinally . 50 jil of APA-IgG (45mg/ml) was allowed to diffuse into one-half
of the gel (shown at the bottom) for 2 days at 4°C. The other half of the gelwas cut into 15
equal sections, homogenized in 1.5 mf 0.1 M Tris buffer, pH 8, using a 1 ml syringe equipped
with ano . 22 guage needle andthe entire solution was incubated on 12°I-labeled fibrin-coated
plates for 2 h at 37°C . The final mixture (total incubation vol of 2 ml) contained 8 ug of dog
plasminogen . The amount of '25I-labeled FDP released from the plate by the plasminogen
activator contained in each gel section wasassayed as described in the Materialsand Methods
and is plotted in the top half of the figure .J. K . CHRISTMAN, S . C. SILVERSTEIN, AND G. ACS
FIG. 4 . Immunoduffusion of plasminogen activator in fibrin and plasminogen containing
agar . Center well, 20 ,l APA-IgG. Well 1, 10 u1 stage 5 plasminogen activator . Well 2, 10 M1
isoelectrically purified plasminogen activator . Immunodiffusionwas allowed to procede at 4°C
for 2 days after which the slide was incubated at 37°C for 12 h in a humidified atmosphere to
allow development of the zones of fibrin lysis .
TABLE III
Species Specificity of Antibody to SV40-Transformed Hamster Fibroblast Plasminogen
Activator
lagAPA-IgG protein/10 5
cells
Ag APA-IgGprotein/ml
Control activity*
A . Effect on the release of fibrin degradation products by several cell lines
Control activity$
B. Effect on action ofhuman plasminogen activators
Urokinase
￿
580
￿
95-100
Released enzyme, melanoma (RPMI-8352)
￿
580
￿
95-123
427
* For each set of assays sufficient cells oftheindicated type were plated to releaseapproximately80%
of the available radioactive fibrin as FDP after 24 h incubation at 37°C . Thenumber of cells plated
on each assay dish were as follows : SV40 hamster cells, 2 x 105 ; 13 559 melanoma cells, 5 x 105 ; B,e
melanoma cells, 5 x 105 ; andmousemammarytumor cells, 2 x 10 5 . Allother details as in Materials
and Methods or Fig. 2 .
$ For each set of assays, the incubation mixture contained sufficient enzyme to release 50-80% of
available radioactivity in 2 h at 37°C . Humanurokinasewas purchased from Nutritional Biochemi-
cals Div., International Chemical & Nuclear Corp ., Cleveland, Ohio, and HF (Methods) from a line
of human melanoma cells (6) was the kind gift of DoctorsD. B. Rifkin andE. Reich . All details as
in Fig. 1 .
plasminogen activators from murine and human cell lines to activate
plasminogen. In each experiment, the number of cells plated was sufficient to
release approximately80% of the 1 251-labeled fibrin bound to the dish in 24 h at
37°C . The maximal amount of APA-IgG added to each assay plate is indicated .
SV40-transformed hamster fibroblasts 175 0-11
13,59mouse melanoma 175 116-167
B,emouse melanoma 175 95-100
Mousemammarytumor 260 100428
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In no case were lower levels of APA-IgG inhibitory. Addition of APA-IgG did not
alter the appearance, slow the growth, or inhibit the capacity ofthese tumor cells
to convert plasminogen to plasmin. Similarly, APA-IgG had no inhibitory effects
on plasminogen activators obtained from normal (urokinase) or transformed
(melanoma) human cells (Table III B). These data indicate that the antigenic
determinants recognized by APA-IgG are not shared by plasminogen activators
from other species. They also provide conclusive evidence that APA-IgG directly
inhibits the enzymatic function of the plasminogen activator released by
SV40-transformed hamster cells and that APA-IgG does not inhibit plasmin
degradation of the fibrin substrate.
Effect of APA-IgG on Plasminogen Activators from Cell Lines and Primary
Explants of Hamster Tissues. Having established that APA-IgG does not
inhibit plasminogen activators from species other than hamster, we examined
the effect ofAPA-IgG upon plasminogen activators produced by two hamster cell
lines. The cell lines chosen were DON [a diploid line derived from normal
Chinese hamster lung (18)] and HaK [derived from normal golden Syrian
hamster kidney (18)]. When these cell lines were plated on 1251-labeled
fibrin-coated tissue culture dishes in the presence of a suitable source of
plasminogen (dog serum), 1251-labeled FDP were released into the medium.
Continued incubation of the cells under these conditions stimulated the
formation of sufficient plasmin to cause release ofthe cells from the surface (see
for example Fig. 1 a). Addition of APA-IgG to the culture medium completely
inhibited the fibrinolytic activity of DON lung cells (Table IV A), and the cells
remained attached to the dish (see for example Fig. 1 b). In contrast, APA-IgG
had no inhibitory effect on either the fibrinolytic activity of HaK kidney cells
(Table IV A) or on their subsequent release from the culture dish. Similar results
were obtained when the plasminogen activator(s) from DON and HaK were
tested in cell-free assays (Table IV B). APA-IgG did not block plasminogen
activation by either the released or cell-bound enzyme from kidney but
effectively inhibited the activity of the cell-bound enzyme from lung.
These results indicate that hamster cells can make at least two
immunologically distinct forms of plasminogen activators and that the DON
lung cells produce plasminogen activator(s) which share antigenic determinants
with the enzyme produced by SV40-transformed hamster cells. However, these
data do not resolve whether the plasminogen activator produced by the DON
lung cell line is immunologically similar to the enzyme produced by normal
hamster lung cells. To clarify this point we prepared primary cell cultures from
the lungs, skin, and kidneys of golden Syrian hamster neonates. These cells were
assayed for plasminogen activator after their first passage in culture. Skin
fibroblasts produced no detectable plasminogen activator. In both the lung and
the kidney explants, however, plasminogen-dependent fibrinolytic activity was
readily detected. Addition ofAPA-IgG to the lung cells markedly inhibited their
fibrinolytic activity while similar amounts of APA-IgG had no inhibitory effect
upon the fibrinolytic activity ofthe kidney cells (Table IV A). It should be noted
that the enzyme released by the kidney cells does not destroy the activity of
APA-IgG; APA-IgG whichhas been incubated with kidney cells retainsits ability
to inhibit the plasminogen activatorfrom SV40-transformed hamster cells. TheseJ. K. CHRISTMAN, S. C. SILVERSTEIN, AND G. ACS
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TABLE IV
Effect of Anti-SV40 PlasminogenActivatorIgG on the Capacity of Hamster Cells and
Enzymes to Activate Plasminogen
Cells
￿
Ag APA-IgG protein/105
￿
% Controlactivity cells
A. Effect on the release of fibrin degradation products by cells:
APA-IgGConcentration
Enzyme
￿
(leg protein/ml)
￿
% Control activity
B. Effect on the enzymatic activity of plasminogen activators from HaK and DON cells:
and DON cells:
SolubleHaK plasminogen activator
￿
290
￿
110-290
HaK cell membrane enriched fraction
￿
120
￿
100
DONcell membrane enriched fraction
￿
30
￿
0-5
All procedures and assays were performed as outlined in the legends of Tables I and 11. For each
assay, sufficient cellsof theindicatedtype were plated to release approximately 80% of theavailable
radioactive fibrin as FDP after 24 h incubation at 37°C.
(A) Incubations were for 18-24 h except for the primary lung cells and skin fibroblasts which were
incubated for 48 h. The number of cells plated on each assay dish were as follows: DON, 5 x 105;
HaK, 1-2 x 105 ; SV40 hamster embryo, 2 x 106; primary hamster lung, 3 x 105; primary hamster
kidney, 5 x 106; and primary hamsterskin fibroblasts, 1 x 106.
(B) HaK-secreted enzyme was tested (a) as the unpurified harvest fluid from confluent cell
monolayers, (b) as thestage 3 purified enzyme, and (c) as thestage 5 purified enzyme (see Materials
and Methods and reference 9) . None of these enzyme preparations were inhibited by APA-IgG. IgG
concentration represents the highest concentration used.
findings confirm the immunological cross-reactivity of plasminogen activator
produced by the SV40-transformed hamster cell line with plasminogen activator
from normal hamster lung cells.
Is Plasminogen Activator Present on the Cell Surface?
￿
A major proportion of
SV40-transformed hamster cell-bound plasminogen activator activity
cosediments with a plasma membrane-enriched fraction from these cells (10). To
examine the possibility that plasminogen activator is a surface component of
these transformed hamster cells we took advantage of the capacity of antibodies
directed against cell membrane antigens to initiate C-mediated cytotoxic effects
upon cells displaying these antigens. No deleterious effect on cell viability as
measured by trypan blue exclusion was noted when a suspension of SV40
hamster cells was incubated with APA-IgG and C. Control experiments showed
that these SV40 hamster cells become permeable to trypan blue when they are
incubated with C in the presence of anti-SV40 hamster cell membrane or
anti-SV40 hamster cell immunoglobulin preparations, and that both C and
immune IgG are required (Table V, method 1). Cell monolayers treated with
DON(Chinese hamsterlung) 175 20
HaK (Golden Syrian hamsterkidney) 580 120
SV40 virus-transformed hamster fibroblast 175 0
1° Golden Syrian hamsterlung 75-241 0-20
1° Golden Syrian hamster kidney 175 90-100
1°Golden Syrian hamsterfibroblast 0 No activity430
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TABLE V
Complement-Mediated Cytotoxic Effects of Immunoglobulin Preparations*
This assay was performed by three methods, all of which gave similar results. (Method 1) SV40
hamster cell monolayers in 100 mm petri dishes were washed with PBS, andremoved from the dish
with trypsin (0.25% in PBS). Thecells were mixed with an equal volume of Dulbecco's medium con-
taining 10% fetal bovine serum, pelleted by centrifugation (250 g, 4°C, 10 min) and resuspended in
HBSS at a concentration of 1.0 x 10' cells/ml. Each assay contained 5 x 105 cells, 50 Al of the
indicated antibody preparation, and 50 Al of adsorbed guinea pig C when appropriate. Samples in
which C or antibody were omitted were brought to a final vol of 150 Al with HBSS. The samples
were incubated 30 min at 37°C, immediately added to an equal volume of 0.08% trypan blue in
HBSS, and assayed for cell viability by phase-contrast microscopy. (Method 2) 35 mm Petri dishes
containing 5 x 105 SV40 hamster cells in monolayer culture were washed with PBS and incubated
at 37'C for 30 min with 0.1 ml HBSS, 0.1 ml of the indicated antibody preparation, and 0.1 ml of
absorbed guinea pig C as indicated. Samples in which C or antibody were omitted were brought to
a final vol of 1 ml with HBSS . At the end of the incubation period the medium was removed, andthe
cells were incubated for 5 minat room temperature with 1 ml HBSS containing 0.04% Trypan blue.
The medium wasremoved, acover slip was placed over the monolayers and cell viability was mea-
sured as above. (Method 3) SV40 hamster cells were incubated as in method 2 above with HBSS
andtheindicated antibody preparation. The monolayers were then washed twice with HBSS, incu-
bated an additional 30 min at 37'C with 0.8 ml HBSS, 0.1 ml adsorbed sheep antirabbit IgG, and
0.1 ml adsorbed C as indicated, andassayed for viable cells as in method 2above.
these antibody preparations and C behaved in a similar fashion indicating that
trypsinization of the SV40 hamster cells did not remove surface antigen(s) which
react with APA-IgG (Table V, method 2) . To enhance the sensitivity of the
cytotoxic method we incubated APA-IgG-treated SV40 hamster cells with sheep
antirabbit IgG and C . No cytotoxic effect was noted, even under these conditions.
As expected, cells incubated with anti-SV40 hamster cell membrane or
anti-SV40 hamster cell immunoglobulin preparations and sheep antirabbit IgG
and C were destroyed (Table V, method 3) .
In the course of these experiments we noted that although DON lung cells
activate plasminogen and contain a cell-bound form of plasminogen activator
which is inhibited by APA-IgG, they do not secrete detectable plasminogen
Immunoglobulin Complement
Method 1
Viable cells
Method 2 Method 3
Antiplasminogen activator IgG + >95 >95 >95
- >95 >95 >95
Antihamster membrane IgG + <5 6 Cells lysed
- >95 >95 >95
Antihamster cell IgG + <5 2 cells lysed
- >90 >90 >95
Control rabbit IgG + >95 >95 >95
- + >95 >95 >95
- - >95 >95 NDJ . K. CHRISTMAN, S. C. SILVERSTEIN, AND G. ACS
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activator into serum-free medium. To determine whether plasminogen activation
by lung cells might result from the action of enzyme bound to the cell surface we
incubated DON cells with APA-IgG and C (using methods2 and 3 ofTable V) ; no
cytotoxic effects were noted. In contrast, over 95% of DON cells incubated with
anti-SV40 hamster cell antibody and C were rendered trypan blue positive by
this treatment.
The failure of APA-IgG and C to damage the SV40-transformed hamster cells
is consistent with the hypothesis that plasminogen activator is a secretory
product which is not displayed on the cell's surface. This is the case for most
IgG-secreting plasma cells which do not contain these immunoglobulins on their
surface membranes and are not lysed by C and anti-immunoglobulin antibodies
(19) . However, it is also possible that the amount of enzyme contained on the
cell's surface maybe too small to be detected by the cytotoxicity tests employed.
Discussion
The basic goal of these studies is the elucidation of the role, if any, of
plasminogen activators in malignant transformation and tumorigenesis. For this
purpose we purified the plasminogen activator from SV40 virus-transformed
hamster cells, prepared antibodies against it, and using these antibodies as
probes, compared the immunological determinants of the SV40 hamster cell
enzyme with those of plasminogen activators produced by normal and malignant
cells.
Our results allow three major conclusions to be drawn: (a) Multiple isozymme2
of plasminogen activator exist in normal hamster tissues. Antibodies prepared
against SV40 hamster cell plasminogen activator inhibited the enzymes
produced by primary hamster lung cells and by the DON diploid hamster lung
cell line but had no effect on the plasminogen activator(s) of HaK heteroploid
hamster kidney cells or of primary hamster kidney cells. These data are
consistent with the findings of Kucinski et al . (3) and Aoki and von Kaulla (20) .
They found that antibodies to human urokinase were specific for the
plasminogen activators from otherhumantissues.
(b) A plasminogen activator produced by an SV40 virus-transformed ham-
ster cell line shares immunological determinants with the isozyme produced by
normal hamster lung cells. Plasminogen activators produced by lung cells were
inhibited by antibodies directed against the enzyme produced by a malignantly
transformed cell line. Since this SV40 virus-transformed cell line wascloned from
a culture of randomly transformed hamster embryo cells, we do not know the cell
type or tissue from which the original transformant arose. It is possible that the
original SV40 hamster cell transformant was a lung cell and that the tissue
specificity of the APA-IgG reflects this fact. Alternatively, the tissue of origin
of the original transformant may be irrelevant. The transforming virus may
activate the production of one of several isozymes encoded in the cellular
genome. Such activation could be random (SV40 transformants of the same cell
We use the term isozyme in its most general context as originally proposed by Markert and
Moller (21), namely enzymes occurring in a single species in more than one structural form.432
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type would produce any one of several possible isozymes of plasminogen
activator), or specific (all SV40 transformants of cells from a given species would
produce the same isozyme regardless of the tissue of origin of the cell trans-
formed). Convincing evidence has already been presented (4, 5) that the plas-
minogen activators produced by Rous sarcoma virus-transformed cells are not
encoded by the viral genome. It seems likely that a similar situation will prevail
in the case of SV40.
(c) Different malignant cell lines derived from the same species produce
immunologically distinct plasminogen activators. HaK cells, a heteroploid line
derived from adult kidney tissue, has been reported to cause tumors when
injected intracerebrally into hamsters (18) . Thus these cells, which are derived
from the same species as the SV40-transformed hamster cells and are by
definition a transformed line, produce a plasminogen activator which is
immunologically different from the enzyme secreted by SV40 hamster cells.
Recently, we have found that two independently derived lines of Rous sarcoma
virus-transformed hamster cells and one line of benzoapyrene-transformed
hamster embryo cells produce plasminogen activators which are not inhibited by
the antibody (APA-IgG) directed against the plasminogen activator secreted by
SV40 hamster cells. Thus, no one isozyme of plasminogen activator is
characteristic of transformed cells. As discussed above, we have not yet
established whether the isozyme expressed by a given clone of transformed cells
is characteristic of the tissue or cell type from which the original transformant is
derived or of the agent which initiates the transforming event. Moreover, we do
not yet know how many different isozymes of plasminogen activator are produced
in a single species and whether each tissue produces a specific isozyme. If in fact
each tissue does produce a characteristic plasminogen activator and if the
isozyme produced by a given tumor is determined by the cell type or tissue in
which the tumor originated, not by the nature of the transforming agent,
isozymes of plasminogen activators may be useful for identifying the tissue origin
of tumors. In addition, if these enzymes are released into the circulation of
tumor-bearing individuals, antibodies directed against specific isozymes may
have diagnostic value.
Summary
Rabbits were immunized against the plasminogen activator released by SV40
virus-transformed hamster embryo cells. The resulting antiplasminogen
activator immunoglobulin (APA-IgG) inhibited the enzymatic activity of the
plasminogen activator produced by SV40-transformed hamster cells, and the
plasmin-catalyzed release of these cells from the tissue culture dish. APA-IgG
was not cytotoxic for these cells even in the presence of complement and did not
inhibit their release of plasminogen activator. APA-IgG formed a single
precipitin line in immunodiffusion plates using highly purified plasminogen
activator as antigen. APA-IgG inhibited the plasminogen activator produced by
newborn hamster lung cells and by an established diploid line (DON) of hamster
lung cells, but did not inhibit plasminogen activators produced by normal or
transformed hamsterkidney cells or by cellsof other species (mouse and human) .
We derive three major conclusions from these data: (a) There are severalJ. K. CHRISTMAN, S. C. SILVERSTEIN, AND G. ACS
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immunologically distinguishable forms (isozymes) of plasminogen activators in
normal hamster tissues. (b) The plasminogen activators produced by normal
hamster lung cells and by SV40 virus-transformed hamster embryo cells share
antigenic determinants and are presumably the same isozyme. (c) The
plasminogen activators produced by different hamster tumor cells do not share
antigenic determinants and are presumably different isozymes.
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